Rappaport R, Brauner R, Mugnier E
Unité d'Endocrinologie Pédiatrique et Diabète, Hôpital des Enfants-Malades, Paris.
Ann Endocrinol (Paris). 1988;49(4-5):319-22.
The use of human growth hormone is being extensively reevaluated in children with hypopituitarism, as we enter a new phase with sufficient supply of recombinant hGH. Simultaneously much emphasis has been placed on the methods of measurement of GH secretion in order to define a more appropriate cutoff level defining partial GH deficiency. Among non conventional indications of hGH, Turner syndrome has turned out to be most important with very encouraging short term results. The extension of hGH therapy to other clinical groups, as non endocrine short stature is still under careful investigation in many groups. A long term follow-up is necessary to assess the true benefit of such a treatment and the absence of metabolic and immunological side effects. We should keep a critical attitude toward the very likely extension of the use of hGH considering that many areas, principally in adults, remain to be explored.
随着我们进入重组人生长激素供应充足的新阶段，垂体功能减退患儿使用人生长激素的情况正在得到广泛重新评估。与此同时，人们非常重视生长激素分泌的测量方法，以便确定更合适的临界水平来界定部分生长激素缺乏。在生长激素的非传统适应症中，特纳综合征已被证明是最重要的，短期结果非常令人鼓舞。生长激素疗法在其他临床组中的应用仍在许多组中进行仔细研究，因为非内分泌性身材矮小的情况仍在研究中。需要长期随访以评估这种治疗的真正益处以及是否不存在代谢和免疫副作用。考虑到许多领域，主要是在成人领域，仍有待探索，我们应该对生长激素使用范围极有可能的扩大持批判态度。
